Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO
Augurex Life Sciences Corp., a leader in early autoimmune disease diagnosis, has appointed Neil Klompas as President and CEO, succeeding co-founder Dr. Norma Biln. Dr. Biln will transition to global head of product research and development while remaining Board Chair. Klompas, a veteran life sciences executive with over 30 years of experience, most recently served as President and COO of Zymeworks (NASDAQ: ZYME).
Augurex's key products include JOINTstat®, a diagnostic for autoimmune arthritic diseases, and the upcoming SPINEstat®, a potential first-in-class diagnostic for Ankylosing Spondylitis. Klompas aims to lead Augurex into its next phase of commercial growth, focusing on delivering value to patients and shareholders.
Augurex Life Sciences Corp., leader nella diagnosi precoce delle malattie autoimmuni, ha nominato Neil Klompas Presidente e CEO, succedendo alla co-fondatrice Dr.ssa Norma Biln. La Dr.ssa Biln passerà alla guida globale della ricerca e sviluppo dei prodotti, mantenendo il ruolo di Presidente del Consiglio. Klompas, un veterano del settore delle scienze della vita con oltre 30 anni di esperienza, ha recentemente ricoperto il ruolo di Presidente e COO di Zymeworks (NASDAQ: ZYME).
I prodotti chiave di Augurex includono JOINTstat®, un diagnostico per le malattie artritiche autoimmuni, e il prossimo SPINEstat®, un potenziale diagnostico di prima classe per la Spondilite Anchilosante. Klompas punta a guidare Augurex nella sua prossima fase di crescita commerciale, concentrandosi sulla creazione di valore per pazienti e azionisti.
Augurex Life Sciences Corp., líder en el diagnóstico precoz de enfermedades autoinmunitarias, ha nombrado a Neil Klompas como Presidente y CEO, sucediendo a la cofundadora Dra. Norma Biln. La Dra. Biln asumirá la dirección global de investigación y desarrollo de productos, mientras continúa como Presidenta del Consejo. Klompas, un veterano ejecutivo en ciencias de la vida con más de 30 años de experiencia, se desempeñó recientemente como Presidente y COO de Zymeworks (NASDAQ: ZYME).
Los productos clave de Augurex incluyen JOINTstat®, un diagnóstico para enfermedades artríticas autoinmunitarias, y el próximo SPINEstat®, un diagnóstico de primera clase potencial para la Espondilitis Anquilosante. Klompas tiene como objetivo liderar a Augurex hacia su próxima fase de crecimiento comercial, centrándose en aportar valor a los pacientes y accionistas.
Augurex Life Sciences Corp.는 조기 자가면역 질환 진단의 선두주자로서 Neil Klompas를 대통령이자 CEO로 임명하였으며, 공동 창립자인 Dr. Norma Biln를 이어받았습니다. Biln 박사는 제품 연구 개발의 글로벌 책임자로 전환되며 이사회 의장을 지속합니다. Klompas는 30년 이상의 경험을 가진 생명 과학 분야의 경험자로서, 최근에는 Zymeworks (NASDAQ: ZYME)의 사장 및 COO로 재직했습니다.
Augurex의 주요 제품에는 자가 면역 관절 질환 진단제인 JOINTstat®와 잠재적인 1세대 진단제인 SPINEstat®가 포함되어 있습니다. Klompas는 환자와 주주들에게 가치를 제공하는 데 집중하여 Augurex를 상업적 성장의 다음 단계로 이끌 계획입니다.
Augurex Life Sciences Corp., un leader dans le diagnostic précoce des maladies auto-immunes, a nommé Neil Klompas Président et CEO, succédant à la co-fondatrice Dr. Norma Biln. Dr. Biln deviendra responsable mondiale de la recherche et du développement des produits tout en restant présidente du conseil. Klompas, un vétéran de l'industrie des sciences de la vie avec plus de 30 ans d'expérience, a récemment été Président et COO de Zymeworks (NASDAQ: ZYME).
Les produits phares d'Augurex incluent JOINTstat®, un diagnostic pour les maladies arthritiques auto-immunes, et le prochain SPINEstat®, un potentiel diagnostic de première classe pour la spondylarthrite ankylosante. Klompas vise à guider Augurex vers sa prochaine phase de croissance commerciale, en se concentrant sur la création de valeur pour les patients et les actionnaires.
Die Augurex Life Sciences Corp., führend in der frühen Diagnose von Autoimmunerkrankungen, hat Neil Klompas zum Präsidenten und CEO ernannt, der die Nachfolge der Mitbegründerin Dr. Norma Biln antritt. Dr. Biln wird die globale Leitung für Produktforschung und -entwicklung übernehmen und bleibt weiterhin Vorsitzende des Vorstands. Klompas ist ein erfahrener Manager im Bereich der Lebenswissenschaften mit über 30 Jahren Erfahrung und war zuletzt Präsident und COO von Zymeworks (NASDAQ: ZYME).
Zu den Schlüsselprodukten von Augurex gehören JOINTstat®, ein Diagnosemittel für autoimmunbedingte Arthritis-Erkrankungen, und das kommende SPINEstat®, ein potenzielles Diagnosetool der ersten Klasse für ankylosierende Spondylitis. Klompas hat sich zum Ziel gesetzt, Augurex in die nächste Phase des kommerziellen Wachstums zu führen, wobei der Fokus auf der Schaffung von Werten für Patienten und Aktionäre liegt.
- Appointment of experienced healthcare executive Neil Klompas as new President and CEO
- Development of SPINEstat®, a potential first-in-class diagnostic for Ankylosing Spondylitis
- Retention of co-founder Dr. Norma Biln as global head of product research and development and Board Chair
- None.
- Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO
- Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors
“I have long believed that the key to successfully treating and managing a disease is its early and accurate detection and diagnosis. 14-3-3η and JOINTstat®, Augurex’s novel diagnostic for autoimmune arthritic diseases, provides Rheumatologists with an important tool to achieve this.” said Mr. Klompas. “Our next diagnostic, SPINEstat®, has the potential to transform clinical practice as a first-in-class diagnostic for Ankylosing Spondylitis, enabling physicians to make a timely and accurate diagnosis of this prevalent autoimmune disorder. I look forward to building upon the many successes of Dr. Biln and the entire Augurex team, and to leading Augurex into its next phase of commercial growth where we deliver exceptional value to our patients and shareholders.”
“This is a very exciting time for Augurex, and for me as a founder,” said Dr. Biln. “At each stage of a company’s growth, a unique leadership skillset is needed to take the company to the next level, and Mr. Klompas has the strategic and financial acumen, expertise and high-paced results-driven approach to take us there.” Dr. Biln adds, “I look forward to Mr. Klompas building the future for Augurex’s key stakeholders, starting with patients through to its customers, suppliers and shareholders. I welcome Mr. Klompas, on behalf of the whole team at Augurex and our Board of Directors.”
A seasoned life sciences executive, Mr. Klompas has been involved in healthcare and biotechnology for over 30 years in various senior leadership roles spanning operational, financial and research and development responsibilities. Most recently, he served as President and Chief Operating Officer of Zymeworks (NASDAQ: ZYME), where he had previously held the role of Chief Financial Officer. Prior to that, Mr. Klompas’ experience included roles with KPMG, a global financial services firm, in both
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, available as 14-3-3η in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806697030/en/
Nima Mazinani
604-674-8231
info@augurex.com
Source: Augurex Life Sciences Corp.
FAQ
Who is the new President and CEO of Augurex Life Sciences Corp?
What is Augurex's main product for diagnosing autoimmune arthritic diseases?
What is SPINEstat® and what is its potential impact?
What was Neil Klompas' previous role before joining Augurex?
